Evidence map›Paper›PMID 34162830›Full record

ArticleCell death & disease2021

Circular RNA hsa_circ_0110389 promotes gastric cancer progression through upregulating SORT1 via sponging miR-127-5p and miR-136-5p.

Min Liang, Wenxia Yao, Boyun Shi, Xiongjie Zhu, Rui Cai, Zhongjian Yu, Weihong Guo, Huaiming Wang, Zhijie Dong, Mingzhen Lin and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Min Liang *Department of Oncology, Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, 510700, Guangzhou, China.
Wenxia Yao *Department of Center Laboratory, Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, 510700, Guangzhou, China.ORCID 0000-0003-1677-9613
Boyun Shi *Department of Oncology, Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, 510700, Guangzhou, China.
Xiongjie ZhuMedical Oncology Department, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Medical University, 510095, Guangzhou, China.
Rui CaiMedical Oncology Department, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Medical University, 510095, Guangzhou, China.
Zhongjian YuMedical Oncology Department, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Medical University, 510095, Guangzhou, China.
Weihong GuoDepartment of General Surgery, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China.
Huaiming WangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Zhijie DongDepartment of Center Laboratory, Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, 510700, Guangzhou, China.
Mingzhen LinDepartment of Center Laboratory, Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, 510700, Guangzhou, China.
Xinke ZhouDepartment of Oncology, Guangzhou Key Laboratory of Enhanced Recovery after Abdominal Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, 510700, Guangzhou, China. zxkstarr@yeah.net.ORCID 0000-0001-7840-3123
Yanfang ZhengMedical Oncology Department, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Medical University, 510095, Guangzhou, China. zheng2020@gzhmu.edu.cn.ORCID 0000-0002-5591-6425
Guangzhou Medical University · CNGuangzhou Medical University Cancer Hospital · CNNanfang Hospital · CNShantou University · CN

Funding

Guangdong Medical Research Foundation (Guangdong Province Medical Research Foundation) A2019466National Natural Science Foundation of China (National Science Foundation of China) 81974434
6 · The paper itself

Abstract

Increasing studies have found that circular RNAs (circRNAs) are aberrantly expressed and play important roles in the occurrence and development of human cancers. However, the function of circRNAs on environmental carcinogen-induced gastric cancer (GC) progression remains poorly elucidated. In the present study, hsa_circ_0110389 was identified as a novel upregulated circRNA in malignant-transformed GC cells through RNA-seq, and subsequent quantitative real-time PCR verified that hsa_circ_0110389 was significantly increased in GC tissues and cells. High hsa_circ_0110389 expression associates with advanced stages of GC and predicts poor prognosis. Knockdown and overexpression assays demonstrated that hsa_circ_0110389 regulates proliferation, migration, and invasion of GC cells in vitro. In addition, hsa_circ_0110389 was identified to sponge both miR-127-5p and miR-136-5p and SORT1 was validated as a direct target of miR-127-5p and miR-136-5p through multiple mechanism assays; moreover, hsa_circ_0110389 sponged miR-127-5p/miR-136-5p to upregulate SORT1 expression and hsa_circ_0110389 promoted GC progression through the miR-127-5p/miR-136-5p-SORT1 pathway. Finally, hsa_circ_0110389 knockdown suppressed GC growth in vivo. Taken together, our findings firstly identify the role of hsa_circ_0110389 in GC progression, which is through miR-127-5p/miR-136-5p-SORT1 pathway, and our study provides novel insight for the identification of diagnostic/prognostic biomarkers and therapeutic targets for GC.

Indexed as

Adaptor Proteins, Vesicular TransportAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsNeoplasm InvasivenessRNA, CircularAdaptor Proteins, Vesicular TransportMicroRNAsMIRN127 microRNA, humanMIRN136 microRNA, humanRNA, CircularSortilin

Identifiers

PMID34162830
PMCPMC8222372
OpenAlexW3174163191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.